Adding lanreotide to everolimus significantly prolonged progression-free survival compared with everolimus alone in patients with gastroenteropancreatic neuroendocrine tumors, a phase 3 trial found.

Ipsen will be launching a new pre-filled syringe for its blockbuster rare disease drug Somatuline (lanreotide) in the EU. The new design was based on several studies, involving patients ...

Everolimus plus lanreotide resulted in a progression-free survival of 29.7 months in patients with gastroenteropancreatic neuroendocrine tumors, compared with 11.5 months with everolimus monotherapy.

Bristol-Myers Squibb has won FDA approval for the first LAG-3 inhibitor drug ahead of its rivals in cancer immunotherapy, including Merck & Co. The US regulator cleared BMS' LAG-3 drug relatlimab ...

“While lanreotide and everolimus have each previously demonstrated the ability to extend progression-free survival in patients with gastroenteropancreatic neuroendocrine tumors, combination treatment ...